000079034 001__ 79034 000079034 005__ 20230914083227.0 000079034 0247_ $$2doi$$a10.3389/fphar.2019.00203 000079034 0248_ $$2sideral$$a111572 000079034 037__ $$aART-2019-111572 000079034 041__ $$aeng 000079034 100__ $$aJagust, P. 000079034 245__ $$aMetabolism-Based Therapeutic Strategies Targeting Cancer Stem Cells 000079034 260__ $$c2019 000079034 5060_ $$aAccess copy available to the general public$$fUnrestricted 000079034 5203_ $$aCancer heterogeneity constitutes the major source of disease progression and therapy failure. Tumors comprise functionally diverse subpopulations, with cancer stem cells (CSCs) as the source of this heterogeneity. Since these cells bear in vivo tumorigenicity and metastatic potential, survive chemotherapy and drive relapse, its elimination may be the only way to achieve long-term survival in patients. Thanks to the great advances in the field over the last few years, we know now that cellular metabolism and stemness are highly intertwined in normal development and cancer. Indeed, CSCs show distinct metabolic features as compared with their more differentiated progenies, though their dominant metabolic phenotype varies across tumor entities, patients and even subclones within a tumor. Following initial works focused on glucose metabolism, current studies have unveiled particularities of CSC metabolism in terms of redox state, lipid metabolism and use of alternative fuels, such as amino acids or ketone bodies. In this review, we describe the different metabolic phenotypes attributed to CSCs with special focus on metabolism-based therapeutic strategies tested in preclinical and clinical settings. 000079034 536__ $$9info:eu-repo/grantAgreement/ES/FEDER/Una manera de hacer Europa$$9info:eu-repo/grantAgreement/ES/ISCIII-FSE/FIS-PI17-00082 000079034 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000079034 590__ $$a4.225$$b2019 000079034 592__ $$a1.228$$b2019 000079034 591__ $$aPHARMACOLOGY & PHARMACY$$b52 / 270 = 0.193$$c2019$$dQ1$$eT1 000079034 593__ $$aPharmacology (medical)$$c2019$$dQ1 000079034 593__ $$aPharmacology$$c2019$$dQ1 000079034 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion 000079034 700__ $$ade Luxan-Delgado, B. 000079034 700__ $$aParejo-Alonso, B. 000079034 700__ $$0(orcid)0000-0002-8624-8757$$aSancho, P. 000079034 773__ $$g10, 203 (2019), [26 pp]$$pFront. pharmacol.$$tFrontiers in Pharmacology$$x1663-9812 000079034 8564_ $$s532355$$uhttps://zaguan.unizar.es/record/79034/files/texto_completo.pdf$$yVersión publicada 000079034 8564_ $$s21491$$uhttps://zaguan.unizar.es/record/79034/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000079034 909CO $$ooai:zaguan.unizar.es:79034$$particulos$$pdriver 000079034 951__ $$a2023-09-13-10:43:29 000079034 980__ $$aARTICLE